<DOC>
	<DOCNO>NCT02420314</DOCNO>
	<brief_summary>This clinical trial evaluate add high-dose ascorbate ( vitamin C ) standard care treatment non-small cell lung cancer ( NSCLC ) adult . All subject receive high-dose ascorbate addition standard treatment .</brief_summary>
	<brief_title>Pharmacological Ascorbate Lung Cancer</brief_title>
	<detailed_description>Standard treatment non-small cell lung cancer ( NSCLC ) involve combined therapy paclitaxel carboplatin . These drug administer every 21 day . This study add high dose ascorbic acid ( 75g per infusion ) twice per week 4 cycle therapy . Participants : - receive high dos intravenous ( IV ) ascorbate two time week 3 week chemotherapy . - blood sample draw measure blood ascorbate level every 21 day The active therapy portion study last 4 month . After complete , participant go back standard therapy cancer . Participants continue life-long follow-up study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>newly diagnose stage IIIB IV non small cell lung cancer . The potential participant must receive firstline cytotoxic therapy . First line EGFR inhibitor ALK inhibitor allow progression therapy . CNS metastasis allow metastasis treat sign progression follow treatment . The potential participant must steroids least 3 day stable . ECOG performance status least 2 absolute neutrophil count ( ANC ) least 1500 cell per mm³ platelet count least 100,000 cell per mm³ hemoglobin least 8 g/dL creatinine within 1.5 time upper limit normal total bilirubin within 1.5 time upper limit normal ALT within 3 time institutional upper limit normal AST within 3 time institutional upper limit normal participant must tolerate 15g ascorbate test infusion ( screen dose ) patient receive prior treatment curative intent must experience treatmentfree interval least 6 month since last treatment participant must pregnant , willing pregnancy test do deem necessary , willing use adequate birth control study know sensitize EGFR mutation ALK gene rearrangement participant yet try EGFR ALK inhibitor therapy 50 % great PDL1 expression receive warfarin therapy tolerate drug substitution active hemoptysis within 1 week screening ( 1/2 teaspoon blood per day ) actively receive insulin time ascorbate infusion G6PD deficiency leptomeningeal disease potential participant follow drug : flecainide , methadone , amphetamine , quinidine , chlorpropamide . know active invasive malignancy lung cancer therapy ( nonmelanoma skin cancer carcinoma situ cervix bladder exempt ) potential participant may enroll , actively receive treatment , therapeutic clinical trial . Observational study ( include image study ) acceptable . uncontrolled intercurrent illness include , limited , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness / social situation would limit compliance study requirement know HIV positive individual enrol trial highdose ascorbate know CYP450 3A4 inducer , result low serum level antiretroviral agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Ascorbate</keyword>
	<keyword>Ascorbic acid</keyword>
	<keyword>Vitamin C</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Non Small Cell Lung Cancer</keyword>
	<keyword>carboplatin</keyword>
	<keyword>paclitaxel</keyword>
</DOC>